NEOG Fundamental Analysis - NEOGEN CORP

Fundamental Rating

Taking everything into account, NEOG scores 3 out of 10 in our fundamental rating. NEOG was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

NEOG had positive earnings in the past year.

In the past year NEOG had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.

Each year in the past 5 years NEOG had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of -31.71%, NEOG perfoms like the industry average, outperforming 41.71% of the companies in the same industry.

Looking at the Return On Equity, with a value of -52.72%, NEOG is in line with its industry, outperforming 48.13% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-31.71%
ROE	-52.72%
ROIC	N/A

ROA(3y)-10.81%

ROA(5y)-4.19%

ROE(3y)-17.92%

ROE(5y)-8.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of NEOG (47.10%) is comparable to the rest of the industry.

In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	47.1%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.72%

GM growth 5Y0.07%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NEOG has about the same amount of shares outstanding.

The number of shares outstanding for NEOG has been increased compared to 5 years ago.

Compared to 1 year ago, NEOG has a worse debt to assets ratio.

2.2 Solvency

NEOG has an Altman-Z score of 0.71. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.

NEOG has a Altman-Z score (0.71) which is comparable to the rest of the industry.

A Debt/Equity ratio of 0.42 indicates that NEOG is not too dependend on debt financing.

NEOG has a Debt to Equity ratio of 0.42. This is comparable to the rest of the industry: NEOG outperforms 44.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.42
Debt/FCF	N/A
Altman-Z	0.71

ROIC/WACCN/A

WACC7.73%

2.3 Liquidity

A Current Ratio of 3.32 indicates that NEOG has no problem at all paying its short term obligations.

NEOG's Current ratio of 3.32 is fine compared to the rest of the industry. NEOG outperforms 60.43% of its industry peers.

A Quick Ratio of 2.22 indicates that NEOG has no problem at all paying its short term obligations.

NEOG has a Quick ratio of 2.22. This is comparable to the rest of the industry: NEOG outperforms 55.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.32
Quick Ratio	2.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.

The earnings per share for NEOG have been decreasing by -10.20% on average. This is quite bad

The Revenue has decreased by -3.20% in the past year.

Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.

EPS 1Y (TTM)-25%

EPS 3Y-9.82%

EPS 5Y-10.2%

EPS Q2Q%-50%

Revenue 1Y (TTM)-3.2%

Revenue growth 3Y19.28%

Revenue growth 5Y16.43%

Sales Q2Q%-4.79%

3.2 Future

Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 0.40% on average per year.

Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.

EPS Next Y11.27%

EPS Next 2Y13.49%

EPS Next 3Y-1.41%

EPS Next 5Y0.4%

Revenue Next Year-7.54%

Revenue Next 2Y-4.24%

Revenue Next 3Y-1.21%

Revenue Next 5Y0.6%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 17.00 indicates a rather expensive valuation of NEOG.

82.35% of the companies in the same industry are more expensive than NEOG, based on the Price/Earnings ratio.

NEOG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.85.

NEOG is valuated correctly with a Price/Forward Earnings ratio of 15.28.

NEOG's Price/Forward Earnings ratio is rather cheap when compared to the industry. NEOG is cheaper than 83.96% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 34.98. NEOG is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	17
Fwd PE	15.28

4.2 Price Multiples

NEOG's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NEOG is cheaper than 77.54% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	15.99

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

PEG (NY)1.51

PEG (5Y)N/A

EPS Next 2Y13.49%

EPS Next 3Y-1.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NEOG!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEOGEN CORP

NASDAQ:NEOG (8/19/2025, 8:07:54 PM)

After market: 5.61 0 (0%)

5.61

+0.07 (+1.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)07-29 2025-07-29/bmo

Earnings (Next)10-08 2025-10-08

Inst Owners117.15%

Inst Owner Change-4.98%

Ins Owners0.2%

Ins Owner Change26.75%

Market Cap1.22B

Analysts78

Price Target6.63 (18.18%)

Short Float %8%

Short Ratio2.93

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-22.76%

Min EPS beat(2)-34.64%

Max EPS beat(2)-10.87%

EPS beat(4)1

Avg EPS beat(4)-13.3%

Min EPS beat(4)-34.64%

Max EPS beat(4)11.56%

EPS beat(8)1

Avg EPS beat(8)-15.08%

EPS beat(12)3

Avg EPS beat(12)39.16%

EPS beat(16)4

Avg EPS beat(16)23.61%

Revenue beat(2)0

Avg Revenue beat(2)-2.03%

Min Revenue beat(2)-3.66%

Max Revenue beat(2)-0.4%

Revenue beat(4)0

Avg Revenue beat(4)-1.34%

Min Revenue beat(4)-3.66%

Max Revenue beat(4)-0.19%

Revenue beat(8)1

Avg Revenue beat(8)-1.4%

Revenue beat(12)2

Avg Revenue beat(12)-1.25%

Revenue beat(16)3

Avg Revenue beat(16)-1%

PT rev (1m)-23.53%

PT rev (3m)-23.53%

EPS NQ rev (1m)-52%

EPS NQ rev (3m)-61.29%

EPS NY rev (1m)0%

EPS NY rev (3m)-14.29%

Revenue NQ rev (1m)-5.87%

Revenue NQ rev (3m)-8.55%

Revenue NY rev (1m)-5.85%

Revenue NY rev (3m)-7.98%

Valuation

		Industry Rank	Sector Rank
PE	17
Fwd PE	15.28
P/S	1.36
P/FCF	N/A
P/OCF	20.91
P/B	0.59
P/tB	N/A
EV/EBITDA	15.99

EPS(TTM)0.33

EY5.88%

EPS(NY)0.37

Fwd EY6.55%

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)0.27

OCFY4.78%

SpS4.12

BVpS9.54

TBVpS-1.86

PEG (NY)1.51

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.71%
ROE	-52.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	47.1%
FCFM	N/A

ROA(3y)-10.81%

ROA(5y)-4.19%

ROE(3y)-17.92%

ROE(5y)-8.21%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.72%

GM growth 5Y0.07%

F-Score3

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0.42
Debt/FCF	N/A
Debt/EBITDA	7.06
Cap/Depr	83.23%
Cap/Sales	11.69%
Interest Coverage	N/A
Cash Conversion	46.97%
Profit Quality	N/A
Current Ratio	3.32
Quick Ratio	2.22
Altman-Z	0.71

F-Score3

WACC7.73%

ROIC/WACCN/A

Cap/Depr(3y)84.37%

Cap/Depr(5y)96.63%

Cap/Sales(3y)10.58%

Cap/Sales(5y)8.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-25%

EPS 3Y-9.82%

EPS 5Y-10.2%

EPS Q2Q%-50%

EPS Next Y11.27%

EPS Next 2Y13.49%

EPS Next 3Y-1.41%

EPS Next 5Y0.4%

Revenue 1Y (TTM)-3.2%

Revenue growth 3Y19.28%

Revenue growth 5Y16.43%

Sales Q2Q%-4.79%

Revenue Next Year-7.54%

Revenue Next 2Y-4.24%

Revenue Next 3Y-1.21%

Revenue Next 5Y0.6%

EBIT growth 1Y-102.86%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year137.27%

EBIT Next 3Y34.41%

EBIT Next 5Y19.96%

FCF growth 1Y39.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y65.17%

OCF growth 3Y-5.05%

OCF growth 5Y-7.47%

NEOGEN CORP (NEOG) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens